GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Liquidia Corp (NAS:LQDA) » Definitions » EPS without NRI

Liquidia (Liquidia) EPS without NRI : $-1.16 (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Liquidia EPS without NRI?

Liquidia's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-0.42. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.16.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 12.60% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 33.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Liquidia's EPS without NRI or its related term are showing as below:

LQDA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 6.4   Med: 28.3   Max: 54.8
Current: 12.6

During the past 8 years, Liquidia's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 54.80% per year. The lowest was 6.40% per year. And the median was 28.30% per year.

LQDA's 3-Year EPS without NRI Growth Rate is ranked better than
58.91% of 1297 companies
in the Biotechnology industry
Industry Median: 4.9 vs LQDA: 12.60

Liquidia's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.42. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.20.

Liquidia's EPS (Basic) for the three months ended in Dec. 2023 was $-0.42. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.20.


Liquidia EPS without NRI Historical Data

The historical data trend for Liquidia's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Liquidia EPS without NRI Chart

Liquidia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial -2.57 -1.76 -0.70 -0.65 -1.17

Liquidia Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.09 -0.14 -0.36 -0.24 -0.42

Competitive Comparison of Liquidia's EPS without NRI

For the Biotechnology subindustry, Liquidia's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Liquidia's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Liquidia's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Liquidia's PE Ratio without NRI falls into.



Liquidia EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Liquidia  (NAS:LQDA) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Liquidia EPS without NRI Related Terms

Thank you for viewing the detailed overview of Liquidia's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Liquidia (Liquidia) Business Description

Traded in Other Exchanges
Address
419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH). It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension.
Executives
Rajeev Saggar officer: Chief Medical Officer 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Jason Adair officer: V.P. Crp Dvlpmnt and Strtgy C/O LIQUIDIA TECHNOLOGIES, INC., 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Paul B Manning director, 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Roger Jeffs director
Caligan Partners Lp director, 10 percent owner, other: See Remarks 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Robert A Lippe officer: Chief Operations Officer C/O ALEXZA PHARMACEUTICALS, INC., 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Scott Moomaw officer: SVP, Commercial P.O. BOX 110085, RESEARCH TRIANGLE PARK NC 27709
Michael Kaseta officer: Chief Financial Officer 7100 WEST CREDIT AVENUE, SUITE 101, MISSISSAUGA A6 L5N OE4
Russell Schundler officer: General Counsel P.O. BOX 110085, RESEARCH TRIANGLE PARK NC 27709
Arthur S Kirsch director 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
David Edward Johnson 10 percent owner 590 MADISON AVENUE, NEW YORK NY 10022
Katherine Rielly-gauvin director 419 DAVIS DRIVE, MORRISVILLE NC 27560
Raman Singh director C/O LIQUIDIA TECHNOLOGIES, INC., 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Joanna Horobin director 215 FIRST STREET, SUITE 440, CAMBRIDGE MA 02142
Stephen M Bloch director 285 RIVERSIDE AVENUE, SUITE 250, WESTPORT CT 06880